Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: jackie who wrote (10809)	7/16/1999 3:11:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Having predicted the demise of the biotech industry as long as the FDA insist on evaluating efficacy, I just wondered how much of a case the industry has made to the life, health and auto casualty industries that they should consider providing capital to biotech companies. The sums required by biotechs would be chump change for the insurance industry. They would apply their normal risk reward criteria but breakthroughs by the industry would also reduce insurance claims. Without a doubt for the life insurance industry where each day of life extension equals additional profit. One could argue that the less care provided and the faster a patient dies the lower the cost for health care, but doubt that. Better treatment overall should mean fewer days in the hospital.